Nanobiotix S.A. Overview
Pro stress-test →Nanobiotix is a late-stage clinical biotechnology company pioneering the discovery, development, manufacture, and commercialization of disruptive, physics-based nanotherapeutics. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has secured strategic partnerships and non-dilutive financing to advance its oncology pipeline.
Strategic Profile
Pro stress-test →Nanobiotix is engaged in a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, for the co-development and commercialization of the first-in-class radioenhancer, with the development plan initially focused on cancers of the head, neck, and lungs. The company took a non-dilutive strategic royalty monetization with HCRx, saw continued advancement of the JNJ-1900 (NBTXR3) program with completion of the Phase 3 head and neck cancer study sponsorship transfer to J&J, and its Curadigm Nanoprimer program is rapidly emerging as a long-term growth driver.
Competitive Landscape
Pro stress-test →Nanobiotix competes in the oncology nanotherapy and radiotherapy enhancement space against emerging biotech competitors. Comparable biotech companies include Inhibrx Biosciences with a market cap of $1.078B and Innate Pharma S.A. with a market cap of $160.738M. The company's unique physics-based approach and J&J partnership provide competitive advantages.
Industry Context
Nanobiotix S.A. operates in Biotechnology/Oncology.
Key facts
Founded: 2003 · Headquarters: Paris, France · Revenue: $10.2M · Market cap: $1.50B